[go: up one dir, main page]

UY37729A - NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 - Google Patents

NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7

Info

Publication number
UY37729A
UY37729A UY0001037729A UY37729A UY37729A UY 37729 A UY37729 A UY 37729A UY 0001037729 A UY0001037729 A UY 0001037729A UY 37729 A UY37729 A UY 37729A UY 37729 A UY37729 A UY 37729A
Authority
UY
Uruguay
Prior art keywords
activity
inhibit
new compounds
therapy
treatment
Prior art date
Application number
UY0001037729A
Other languages
English (en)
Inventor
Xin Hao
Xin Ma
Feng Ren
Zehong Wan
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY37729A publication Critical patent/UY37729A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos que inhiben la actividad de Nav1,7, a composiciones farmacéuticas que los contienen y a su uso en terapia para el tratamiento de enfermedades mediadas por la actividad de Nav1,7.
UY0001037729A 2017-05-11 2018-05-09 NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 UY37729A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2017083938 2017-05-11

Publications (1)

Publication Number Publication Date
UY37729A true UY37729A (es) 2019-01-02

Family

ID=64104337

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037729A UY37729A (es) 2017-05-11 2018-05-09 NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7

Country Status (4)

Country Link
AR (1) AR112187A1 (es)
TW (1) TW201908310A (es)
UY (1) UY37729A (es)
WO (1) WO2018205948A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020199683A1 (zh) * 2019-04-04 2020-10-08 上海海雁医药科技有限公司 氮杂环取代的磺酰基苯甲酰胺衍生物、其制法与医药上的用途
CA3150748A1 (en) 2019-08-23 2021-03-04 Mochida Pharmaceutical Co., Ltd. Method for producing heterocyclidene acetamide derivative
EP4019485B1 (en) 2019-08-23 2024-08-07 Mochida Pharmaceutical Co., Ltd. Method for producing heterocyclidene acetamide derivatives
CN112028816B (zh) * 2020-09-11 2022-10-14 江阴迈康升华医药科技有限公司 一种取代异吲哚啉的合成方法
WO2023028056A1 (en) 2021-08-24 2023-03-02 Genentech, Inc. 3-amino piperidyl sodium channel inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2427441B1 (en) * 2009-05-04 2016-12-14 Agios Pharmaceuticals, Inc. Pkm2 activators for use in the treatment of cancer
CA2852796A1 (en) * 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
KR20150074122A (ko) * 2012-10-26 2015-07-01 머크 샤프 앤드 돔 코포레이션 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 벤족사졸리논 화합물

Also Published As

Publication number Publication date
TW201908310A (zh) 2019-03-01
AR112187A1 (es) 2019-10-02
WO2018205948A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2017011851A2 (es) Compuestos novedosos
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
GT201600010A (es) Derivaods de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2020004678A (es) Uso de profarmacos de riluzol para tratar ataxias.